Display options
Cite
Solmaz U, Dereli L, Demirtaş GS, et al. An analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center. Turk J Obstet Gynecol. 2015;12(3):158-163doi: 10.4274/tjod.33602.
Solmaz, U., Dereli, L., Demirtaş, G. S., Ekin, A., Mat, E., Gezer, C., Solmaz Hasdemir, P., Sayhan, S., Sancı, M., & Aşkar, N. (2015). An analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center. Turkish journal of obstetrics and gynecology, 12(3), 158-163. https://doi.org/10.4274/tjod.33602
Solmaz, Ulaş, et al. "An analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center." Turkish journal of obstetrics and gynecology vol. 12,3 (2015): 158-163. doi: https://doi.org/10.4274/tjod.33602
Solmaz U, Dereli L, Demirtaş GS, Ekin A, Mat E, Gezer C, Solmaz Hasdemir P, Sayhan S, Sancı M, Aşkar N. An analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center. Turk J Obstet Gynecol. 2015 Sep;12(3):158-163. doi: 10.4274/tjod.33602. Epub 2015 Sep 15. PMID: 28913061; PMCID: PMC5558390.
Copy Download .nbib Format: NLM
Share it on

Turk J Obstet Gynecol. 2015 Sep;12(3):158-163. doi: 10.4274/tjod.33602. Epub 2015 Sep 15.

An analysis of 37 patients with uterine leiomyosarcoma at a high-volume cancer center.

Turkish journal of obstetrics and gynecology

Ulaş Solmaz, Levent Dereli, Gülşah Selvi Demirtaş, Atalay Ekin, Emre Mat, Cenk Gezer, Pınar Solmaz Hasdemir, Sevil Sayhan, Muzaffer Sancı, Niyazi Aşkar

Affiliations

  1. Tepecik Education and Research Hospital, Clinic of Gynecologic Oncology, ?zmir, Turkey.
  2. Tavas State Hospital, Clinic of Obstetrics and Gynecology, Denizli, Turkey.
  3. Tepecik Education and Research Hospital, Clinic of Pathology, ?zmir, Turkey.
  4. Ege University Faculty of Medicine, Department of Obstetrics and Gynecology, ?zmir, Turkey.

PMID: 28913061 PMCID: PMC5558390 DOI: 10.4274/tjod.33602

Abstract

OBJECTIVE: To evaluate the clinicopathologic characteristics, treatment methods, survival, and prognosis of uterine leiomyosarcoma (ULMS).

MATERIALS AND METHODS: All patients with ULMS who were treated between January 1998 and October 2012 were retrospectively reviewed. A total of 37 women who met the inclusion criteria were included in the present study. Univariate and multivariate analyses were used to identify the risk factors for overall survival (OS) and progression-free survival (PFS).

RESULTS: The majority of patients had stage 1 disease (IA, n=9 (24.3%); IB, n=23 (62.1%)). All patients underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Additionally, only pelvic, and pelvic plus para-aortic lymphadenectomy was performed in 5 (13.5%) and 8 (21.6%) women, respectively. Adjuvant treatment was administered to 27 (72.9%) patients. Patients who did not receive adjuvant therapy had stage 1 disease. Recurrences occurred in 5 (13.5%) patients. The median follow-up period was 71 months (range 1-158 months). The 5-year PFS and OS rates were 68% and 74%, for all patients. The 5-year OS rates for women with stage 1 and ≥ stage 2 disease were 82% and 27%, respectively. Multivariate analysis confirmed stage 1 disease as the only independent predictor of both PFS (Odds ratio (OR) 10.955, 95% confidence interval (CI) 1.686-71.181, (p=0.012)) and OS (OR 57.429, 95% CI 3.287-1003.269, (p=0.006)).

CONCLUSIONS: Extensive surgery is not associated with prognosis and stage 1 disease is the only independent good prognostic factor for survival in patients with ULMS.

Keywords: Survival; Uterine leiomyosarcoma; lymph node dissection; stage

Conflict of interest statement

Conflict of Interest: No conflict of interest was declared by the authors.

References

  1. Gynecol Oncol. 2003 Jun;89(3):460-9 - PubMed
  2. Cancer. 2008 Feb 15;112(4):820-30 - PubMed
  3. Gynecol Oncol. 1993 Jul;50(1):105-9 - PubMed
  4. Cancer. 2013 Apr 15;119(8):1555-61 - PubMed
  5. Arch Pathol Lab Med. 2000 Feb;124(2):221-7 - PubMed
  6. World J Surg Oncol. 2009 Apr 08;7:38 - PubMed
  7. Crit Rev Oncol Hematol. 2008 Feb;65(2):129-42 - PubMed
  8. Radiat Oncol J. 2015 Mar;33(1):29-35 - PubMed
  9. Cancer. 1993 Feb 15;71(4 Suppl):1702-9 - PubMed
  10. Am J Surg Pathol. 1994 Jun;18(6):535-58 - PubMed
  11. Am J Obstet Gynecol. 1982 Dec 1;144(7):817-23 - PubMed
  12. Int J Gynecol Cancer. 2015 Jul;25(6):1031-6 - PubMed
  13. Gynecol Oncol. 1996 Jul;62(1):25-32 - PubMed
  14. Gynecol Oncol. 1999 Aug;74(2):196-201 - PubMed
  15. Acta Chir Iugosl. 2006;53(3):67-72 - PubMed
  16. Am J Obstet Gynecol. 1990 Apr;162(4):968-74; discussion 974-6 - PubMed
  17. Acta Oncol. 1990;29(2):185-91 - PubMed
  18. Cancer. 1988 Nov 15;62(10):2239-47 - PubMed
  19. Clin Oncol (R Coll Radiol). 2008 Aug;20(6):470-8 - PubMed
  20. Oncology. 2006;71(5-6):333-40 - PubMed
  21. Gynecol Oncol. 2004 Feb;92(2):648-52 - PubMed
  22. Acta Obstet Gynecol Scand. 2003 Jan;82(1):74-81 - PubMed
  23. Cancer. 2000 Mar 15;88(6):1425-31 - PubMed
  24. J Clin Oncol. 2009 Apr 20;27(12):2066-72 - PubMed
  25. Ecancermedicalscience. 2015 Mar 05;9:515 - PubMed
  26. Gynecol Oncol. 2006 Jan;100(1):166-72 - PubMed
  27. Gynecol Oncol. 2010 Jan;116(1):131-9 - PubMed
  28. Arch Gynecol Obstet. 2009 Jul;280(1):79-85 - PubMed
  29. Radiat Oncol. 2013 May 24;8:128 - PubMed

Publication Types